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Summary: Time-resolved fluoroimmunoassays were used for the detection of pancreatic group I and synovial-
type group II phospholipases A2 in sera of patients suffering from chronic renal failure before and after
haemodialysis. The concentration of group I phospholipase A2 was ten-fold higher in sera of uraemic patients
than in healthy controls. There was no significant difference in the concentrations of group I phospholipase
A2 in serum before and after haemodialysis. The concentration of group II phospholipase A2 was only
marginally increased in sera of uraemic patients, compared with healthy controls. There was no significant
difference in the concentrations of group II phospholipase A2 before and after haemodialysis. The results
indicate that the metabolism of group I phospholipase A2 differs from that of group II phospholipase A2 in
chronic renal failure.
Introduction
Extracellular phospholipases A2J) have been classified
into two types:
pancreatic group I phospholipase A2 and
synovial-type group II phospholipase A2
on the basis of the primary structure of the enzyme
protein. Group I phospholipases A2 contain a cysteine
at position 11 that forms a disulphide bridge with a
cysteine at position 77, whereas group II phospholi-
pases A2 lack these cysteines and the corresponding
disulphide bridge (1). Group I phospholipase A2 is
secreted by pancreatic acinar cells as an enzymatically
inactive proenzyme into the duodenum, where it is
activated by trypsin (2,3). Increased concentrations of
immunoreactive group I phospholipase A2 have been
found in sera of patients suffering from acute pan-
creatitis (4, 5) and pancreatic cancer (4). Increased
') Enzyme:
Phosphatide 2-acylhydrolase, phospholipase A2 (EC 3.1.1.4)
phospholipase A2 catalytic activities and concentra-
tions of group II phospholipase A2 have been meas-
ured in serum in sepsis (6, 7) and in synovial fluid
and serum in rheumatoid arthritis and osteoarthritis
(8). The source of the circulating group II phospho-
lipase A2 is unknown.
High activities and concentrations of pancreatic en-
zymes have been measured in peripheral blood sam-
ples of patients suffering from chronic renal failure
(9, 10). The catalytic activity of phospholipase A2 is
more than eight-fold above normal in uraemic plasma
(11). The concentration of group I phospholipase A2
in serum is elevated in patients suffering from acute
renal dysfunction (12) and chronic renal failure (13).
The purpose of the present study was to investigate
the concentrations of pancreatic and non-pancreatic
phospholipases A2 by specific immunoassays for
group I phospholipase A2 (14) and group II phos-
pholipase A2 (7) in sera of patients suffering from
chronic renal failure. Measurements were done on
serum samples taken before and after haemodialysis
and compared with values of healthy individuals.
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Materials and Methods
Serum samples
Blood samples were taken immediately before and after hae-
modialysis from 10 patients (6 men and 4 women, average age
50 years; range 24—72 years) suffering from chronic renal
failure (five patients had chronic nephritis, one had Wegner's
granulomatosis, gout or malignant hypertension and two pa-
tients had chronic renal failure of unknown etiology). There
were no clinical signs of pancreatic disease in these patients.
Serum was separated and stored at —20 °C until assayed.
Reference material was collected from 20 healthy blood donors
(6 men and 14 women, average age 37 years; range 33—40
years) for the group I phospholipase A2 assay and from 27
blood donors (21 men and 6 women, average age 31 years;
range 24—66 years) for the group II phospholipase A2 assay,
and treated identically to patient sera.
Appara tus
Microtitre plates were washed in a 12-well aspirating-washing
device (Wellwash 4, Denley, Billingham, England) and incu-
bated in a shaking device (Wellmix 3). Fluorescence was meas-
ured with an Arcus fluorometer (Wallac, Turku, Finland)
equipped with an external computer. Data were handled with
a MultiCalc data management software (Wallac).
Standards
Human pancreatic group I phospholipase A2 and recombinant
synovial-type group II phospholipase A2 stock solutions were
diluted with a time-resolved fluoroimmunoassay (TR-FIA) as-
say buffer (Wallac) to give five standard concentrations (0.25,
1.5, 9.0, 54 and 324 μg/l). Group I phospholipase A2 was
purified from human pancreas as described elsewhere (15).
Recombinant synovial-type group II phospholipase A2 was
prepared as described elsewhere (16).
Time-resolved f luoroimmunoassay
Time-resolved fluoroimmunoassays for group I phospholipase
A2 and group II phospholipase A2 were performed as described
earlier (7, 14, respectively).
Statistical analysis
Student's t-test was used unless the difference of variances of
variables warranted the use of Mann-Whitney's U-test. Tests
were performed by using the BMDP statistical software pack-
age.
Results
Group I phospholipase A2
Patients suffering from chronic renal failure had ten-
fold increased group I phospholipase A2 values com-
pared with the reference group, both before and after
haemodialysis (fig. 1). The mean concentration of
group I phospholipase A2 in the reference group was
4.0 μ§/1 (range from 1.7 μ§/1 to 5.6 μ§/1, η = 20). The
mean concentration of group I phospholipase A2 be-
fore haemodialysis was 38.1 μ^Ι (range from 11.1 μ^Ι
to 69.2 μg/l, η = 10) and after haemodialysis 40.4








Concentrations of group I phospholipase A2 (mean, SD)
in the sera of 20 healthy individuals (A, 4.0 ± 1.1 μg/l)
and 10 patients suffering from chronic renal failure
before (B, 38.1 ± 19.5 μg/l) and after (C, 40.4 ± 26.3
μg/l) haemodialysis.
with chronic renal failure. The difference between the
reference samples and the samples taken before and
after haemodialysis was statistically significant
(p < 0.00004). The difference between the samples
taken before and after haemodialysis was not statis-
tically significant (p = 0.832).
Group II phospholipase A2
The mean concentration of group II phospholipase
A2 in the reference group was 5.0 μ§/1 (range from
2.1 μ§/1 to 25.3 μ§/1, η = 27). The mean concentration
of group II phospholipase A2 before haemodialysis
was 7.6 μ§/1 (range from 3.3 μ^ to 20.4 μ^, η = 10)
and after haemodialysis 8.8 μg/l (range from 3.6 μ^
to 25.5 μg/l) in patients with chronic renal failure.
There was no significant difference between group II
phospholipase A2 values in patients with chronic renal
failure before haemodialysis and in the reference
group (p = 0.137, fig. 2). The difference between the
concentrations of group II ATP phospholipase A2 in
samples taken after haemodialysis and those of the
reference group was marginally significant
(p = 0.046). The difference between the samples
taken before and after haemodialysis was not signif-
icant (p = 0.641).
Discussion
The role of phospholipase A2 in acute pancreatitis has
been discussed extensively (4, 17, 18). Recent findings
indicate that non-pancreatic (synovial-type) group II
phospholipase A2 is responsible for the increased cat-
alytic activity of phospholipase A2 in serum in acute
pancreatitis (19,20), as in other inflammatory diseases
(6, 7, 21).
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Fig. 2. Concentrations of group II phospholipase A2 (mean,
SD) in the sera of 27 healthy individuals (A, 5.0 ± 4.3
g/l) and 10 patients suffering from chronic renal failure
before (B, 7.6 ± 5.1 g/l) and after (C, 8.8 ± 6.3 g/l)
haemodialysis.
Patients suffering from chronic renal failure had in-
creased catalytic activities of phospholipase A2 in
plasma (11) and increased concentrations of group I
phospholipase A2 in serum as determined by a radio-
immunoassay (13). Our results confirm these findings.
There was a statistically significant, ten-fold increase
in the concentrations of group I phospholipase A2 in
sera of patients with chronic renal failure compared
with reference material from healthy individuals. The
treatment of uraemia by haemodialysis did not change
the concentrations of group I phospholipase A2 in the
sera of the present patients. Our findings also confirm
that the activities of pancreatic enzymes in serum
increase in patients with end-stage renal disease (10)
and chronic renal failure without pancreatic disease
(9). There were no changes in the elevated amylase
activities during haemodialysis in these patients. Our
patients had advanced chronic renal failure, but no
signs of pancreatic disease. Experimental observations
on nephrectomized and intact rats indicate that group
I phospholipase A2 injected intravenously is elimi-
nated from the circulation mainly by the kidneys (22).
The elevated catalytic activity of phospholipase A2 in
serum is caused by an increase in the concentration
of group II phospholipase A2 in various inflammatory
diseases (6, 7, 19 — 21). The concentration of group
II phospholipase A2 in sera of the present patients
with chronic renal failure was similar to that in the
samples of healthy individuals. Haemodialysis did not
change the concentration of group II phospholipase
A2. These findings suggest that group I and group II
phospholipases A2 are metabolized differently when
their renal elimination from blood plasma is dis-
turbed.
It can be concluded that the concentration of group
I phospholipase A2 is markedly increased in serum in
chronic renal failure, whereas the concentration of
group II phospholipase A2 remains within the refer-
ence interval. Haemodialysis does not affect the con-
centrations of group I and group II phospholipases
A2 in serum in patients with chronic renal failure.
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